Clinical trial · Interventional
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
Anlotinib Plus Anti-PD-1 Antibody AK105 as Third or More-line Therapy for Advanced Pancreatic Cancer: a Prospective, Single-arm, Open-label, Pilot Study
NCT04803851CI-TRIAL-00067419unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
| Anlotinib | — | UNRESOLVED | — |
| Anti-PD-1 Antibody | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anlotinib plus AK105 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment group
- description
- Anlotinib plus AK105
- interventionNames
- Drug: Anlotinib plus AK105
Primary outcomes (1)
- measure
- Disease control rate (DCR) based on RECIST v. 1 1
- timeFrame
- 6 weeks
- description
- Disease control rate (DCR) based on RECIST v. 1 1 by investigators
Secondary outcomes (4)
- measure
- Objective response rate (ORR) based on RECIST V. 1.1
- timeFrame
- 6 weeks
- description
- Objective response rate (ORR) based on RECIST V. 1.1 by investigators
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * locally advanced or metastatic pancreatic cancer (PC), * histologically or cytologically proven diagnosis of adenocarcinoma or adenosquamous carcinoma, * failed to second-line chemotherapy for PC, * 18-75 years of age, * an Eastern Cooperative Oncology Group performance status score of 0 to 1, * adequate organ functions Exclusion Criteria: * had received PD 1 /CTLA 4 antibody treatment * had received anti-VEGFR inhibitors or antibodies
References
Publications (0)
Data not yet available
No reference posted for this study.